Transcatheter Embolization and Occlusion Devices – Market Insights – Asia Pacific

The Asia Pacific TEO device market will experience steady growth over the forecast period, driven by rising cancer incidence, increasing preference for minimally invasive procedures, and clinical evidence supporting embolization and flow-diversion technologies. Neurovascular flow-diverting devices will see the fastest adoption, while emerging indications such as chronic subdural hematoma will further expand procedural volumes. Pricing reforms, including VBP in China, will exert downward pressure on ASPs and alter competitive dynamics; however, higher procedure volumes and continued uptake of innovative devices will sustain moderate revenue growth across the region.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for TEO devices in the Asia Pacific region from 2019 through 2034.

New evidence supporting the use of embolization devices for treating chronic subdural hematoma, in addition to their existing use for tumor indications, will drive growth in neurovascular embolization procedure volumes.

Which embolization devices will see the strongest adoption in the treatment of chronic subdural hematoma?

How will the increasing use of embolization devices for tumor and hyperplasia indications impact overall neurovascular embolization procedure volumes in Asia Pacific region?

Which tumor types are driving the highest procedural growth in embolization procedures?

How will the uptake of embolization procedures in the treatment of chronic subdural hematoma vary across the Asia Pacific region?

Which companies will see market share gains?

Flow-diverting devices are contributing to growth in the Asia Pacific TEO device market.

How will the adoption of flow-diverting devices impact the neurovascular embolization coil and coiling-assist device markets?

Which strategies are competitors adopting to gain a competitive edge over other competitors in the flow-diverting device market?

What will be the impact of emergence of new competitors and products in the Asia Pacific TEO device market?

Liquid embolics are gaining traction in Asia Pacific region due to their versatility in treating aneurysms, cSDH, and peripheral conditions like hemorrhage and tumors.

How will the growing adoption of liquid embolics for cSDH and aneurysm treatment impact overall neurovascular procedure volumes in Asia Pacific?

How will portfolio breadth and clinical evidence influence competitive positioning in the liquid embolic segment?

Positive clinical data will play a key role in driving the adoption of embolization devices, especially the premium-priced devices such as radioembolization spheres and DEBs.

Which clinical trials were recently conducted in this market?

What is the expected impact of these clinical trials on market dynamics?

Reimbursement will be a crucial factor in the adoption of embolization procedures in the cost-conscious Asia Pacific region.

What is the reimbursement scenario in the Asia Pacific region?

How will reimbursement availability impact the TEO device market in future?

How is the use of premium embolization consumables being influenced by the reimbursement changes in Australia and South Korea?

What impact does cost sensitivity have on hospitals’ and doctors’ preferences for local versus foreign equipment vendors in emerging markets?

China’s centralized procurement measures will impact the overall TEO device market.

What are the major changes in the ASPs of various embolization and accessory devices after the implementation of VBP?

How has the market shifted due to bulk volume procurement following VBP implementation for TEO devices?